Suppr超能文献

ICUS、IDUS、CHIP 和 CCUS:诊断标准、与 MDS 的区分及临床意义。

ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.

机构信息

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna,

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna,

出版信息

Pathobiology. 2019;86(1):30-38. doi: 10.1159/000489042. Epub 2018 Jun 1.

Abstract

Various myeloid neoplasms, including the myelodysplastic syndromes (MDS), bear a certain risk of progression to secondary acute myeloid leukemia (sAML). The evolution from low-risk to high-risk MDS and finally to sAML suggests that leukemogenesis is a multistep process. However, even before an overt neoplasm, such as an MDS, develops, "prediagnostic" clonal conditions may be identified. With the advent of large-scale genomic screens, such conditions may be detected quite frequently and early in apparently healthy individuals. Recent data suggest that these conditions increase with age and are indeed associated with an increased risk of the occurrence of MDS or another myeloid neoplasm. In other patients, unexplained cytopenia may be detected and may precede MDS. More recently, diagnostic criteria for potential pre-MDS conditions, including idiopathic cytopenia of uncertain significance and clonal hematopoiesis with indeterminate potential, have been proposed. The current article provides an overview of pre-MDS states and related criteria through which these conditions can be discriminated from each other and from MDS. In addition, the clinical implications and management of pre-MDS states are discussed.

摘要

各种髓系肿瘤,包括骨髓增生异常综合征(MDS),存在向继发性急性髓系白血病(sAML)进展的一定风险。从低危 MDS 向高危 MDS 发展,最终发展为 sAML 的过程提示白血病发生是一个多步骤的过程。然而,即使在明显健康的个体中,显性肿瘤(如 MDS)出现之前,也可能会识别出“前驱性”克隆性疾病。随着大规模基因组筛查的出现,在年龄较大的个体中,这些情况可能会被频繁且早期地检测到。最近的数据表明,这些情况随着年龄的增长而增加,并且确实与 MDS 或其他髓系肿瘤的发生风险增加有关。在其他患者中,可能会检测到不明原因的血细胞减少症,并且可能先于 MDS 发生。最近,提出了潜在 MDS 前驱状态的诊断标准,包括意义未明的特发性血细胞减少症和具有不确定潜能的克隆性造血。本文通过比较 MDS 与 MDS 前驱状态及相关标准,概述了 MDS 前驱状态及其相关标准。此外,还讨论了 MDS 前驱状态的临床意义和管理。

相似文献

1
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Pathobiology. 2019;86(1):30-38. doi: 10.1159/000489042. Epub 2018 Jun 1.
2
MDS overlap disorders and diagnostic boundaries.
Blood. 2019 Mar 7;133(10):1086-1095. doi: 10.1182/blood-2018-10-844670. Epub 2019 Jan 22.
5
ICUS/CCUS/CHIP: basics & beyond.
Expert Rev Hematol. 2017 Oct;10(10):915-920. doi: 10.1080/17474086.2017.1371588. Epub 2017 Sep 1.
6
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:400-410. doi: 10.1200/EDBK_239083. Epub 2019 May 17.
7
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
Best Pract Res Clin Haematol. 2020 Jun;33(2):101137. doi: 10.1016/j.beha.2019.101137. Epub 2019 Dec 15.
8
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Hematology Am Soc Hematol Educ Program. 2015;2015:299-307. doi: 10.1182/asheducation-2015.1.299.
9
Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Clin Chem. 2021 Aug 5;67(8):1062-1070. doi: 10.1093/clinchem/hvab105.

引用本文的文献

3
A Scoping Review on Cognition in Myelodysplastic Syndromes: Advances and Challenges.
Med Sci (Basel). 2025 Feb 7;13(1):15. doi: 10.3390/medsci13010015.
4
Hemizygous Moesin (MSN) Gene Deletion in an Adult With Chronic Neutropenia.
Case Reports Immunol. 2024 Dec 31;2024:3860726. doi: 10.1155/crii/3860726. eCollection 2024.
5
Diagnosis of myelodysplastic syndromes: the classic and the novel.
Haematologica. 2025 Feb 1;110(2):300-311. doi: 10.3324/haematol.2023.284937.
7
How we diagnose Myelodysplastic syndromes.
Front Oncol. 2024 Sep 13;14:1415101. doi: 10.3389/fonc.2024.1415101. eCollection 2024.

本文引用的文献

1
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.
EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26.
2
The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Best Pract Res Clin Haematol. 2017 Dec;30(4):295-300. doi: 10.1016/j.beha.2017.09.009. Epub 2017 Sep 22.
3
Age-related clonal hematopoiesis.
Blood. 2018 Feb 1;131(5):496-504. doi: 10.1182/blood-2017-07-746453. Epub 2017 Nov 15.
4
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.
Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.
5
Individual risk assessment in MDS in the era of genomic medicine.
Semin Hematol. 2017 Jul;54(3):133-140. doi: 10.1053/j.seminhematol.2017.07.002. Epub 2017 Aug 24.
6
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Cancer. 2017 Dec 1;123(23):4608-4616. doi: 10.1002/cncr.30917. Epub 2017 Jul 26.
7
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
N Engl J Med. 2017 Jul 13;377(2):111-121. doi: 10.1056/NEJMoa1701719. Epub 2017 Jun 21.
8
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
Science. 2017 Feb 24;355(6327):842-847. doi: 10.1126/science.aag1381. Epub 2017 Jan 19.
9
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.
10
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验